Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970688 | 0.78 | EPAS1 (0.49) | HSD11B1NR1I2EPAS1HSD11B2SLC6A2 | |
| SCHEMBL2142274 | 0.77 | DHODH (0.42) | HSD11B1NR1I2EPAS1HSD11B2 | |
| SCHEMBL6360307 | 0.75 | MEN1 (0.41) | HSD11B1NR1I2EPAS1HSD11B2 | |
| SCHEMBL27651090 | 0.74 | CYP1A2 (0.51) | HSD11B1NR1I2EPAS1HSD11B2 | |
| SCHEMBL4446770 | 0.72 | EPAS1 (0.49) | HSD11B1NR1I2EPAS1SLC6A2 | |
| SCHEMBL3370619 | 0.72 | MEN1 (0.41) | HSD11B1NR1I2EPAS1 | |
| SCHEMBL4438697 | 0.72 | AR (0.50) | HSD11B1NR1I2EPAS1HSD11B2SLC6A2 | |
| SCHEMBL13069746 | 0.71 | P2RX7 (0.39) | — | |
| SCHEMBL30377367 | 0.71 | SCN9A (0.40) | HSD11B1NR1I2EPAS1 | |
| SCHEMBL363908 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148396-B2 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148396-B2 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148396-B2 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| EP-1888582-B1 | IMIDAZO- AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL MYERS SQUIBB CO (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7579360-B2 | Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579360-B2 | Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579360-B2 | Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090203668-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090203668-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090203668-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| EP-1888582-A1 | IMIDAZO- AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | Brystol-Myers Squibb Company (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006135795-A1 | IMIDAZO- AND TRIAZOLOPYRIDINES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060287357-A1 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203668-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885NR1I2 122/4885EPAS1 2461/4885 |
| US-20060287357-A1 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885NR1I2 113/4885EPAS1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.